SiteOne Therapeutics

San Francisco, United States Founded: 2010 • Age: 16 yrs Acquired By Lilly
NaV1.7 inhibitors are developed for acute and chronic pain treatment.

About SiteOne Therapeutics

SiteOne Therapeutics is a Healthcare company based in San Francisco (United States) founded in 2010 by John V. Mulcahy, and was acquired by Lilly in May 2025. NaV1.7 inhibitors are developed for acute and chronic pain treatment. SiteOne Therapeutics has raised $123.78 million across 13 funding rounds from investors including Amgen, Lilly and NIH. Its chief executive, as recorded, is John V. Mulcahy. SiteOne Therapeutics offers products and services including STC-004. Its focus areas include Life Sciences, Neurology, Drugs and Pain. Its legal entity is SiteOne Therapeutics, Inc. Its competitors include Flexion Therapeutics, Eliem Therapeutics and Zogenix; 3 of its 3 listed competitors have raised funding.

Company details

SiteOne Therapeutics was founded in 2010 in San Francisco, United States, with operations centered in the biotechnology sector for pain management. Selective NaV1.7 inhibitors, derived from naturally occurring small molecules, are advanced as therapeutic candidates. The lead product, targeting moderate to severe pain, is currently in pre-clinical trials. Additional applications include long-acting analgesics and PET imaging diagnostics for various pain conditions.

  • Headquarters San Francisco, United States
  • Founders John V. Mulcahy
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website siteonetherapeutics.com
  • Social LinkedIn
  • Acquired by Lilly (May 2025)
  • Legal Name Siteone Therapeutics, Inc.
Key Metrics
  • Total Equity Funding
    $123.78M (USD)

    in 13 rounds

  • Latest Funding Round
    $100M (USD), Series C

    Dec 2024

  • Investors
    Amgen

    & 15 more

  • Acquired by
    Lilly

    (May 2025)

Products & Services of SiteOne Therapeutics

SiteOne Therapeutics offers a comprehensive portfolio of products and services, including STC-004.

STC-004
Therapeutic Drug

Inhibitor targeting NaV1.8 for treating acute and chronic pain.

Funding Insights of SiteOne Therapeutics

SiteOne Therapeutics has successfully raised a total of $123.78M across 13 strategic funding rounds. The most recent funding activity was a Series C round of $100 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $123.78M
  • Total Rounds 13
  • Last Round Series C β€” $100M
  • First Round $3.12M

    (Dec 2012)

  • Investors Count 15

Latest 10 of 13 funding rounds of SiteOne Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2024$100MSeries C–Novo Holdings
Mar 2024$6MSeries B––
–
May 2023$15MGrant––
Sep 2021$1.64MGrant––
May 2019$1.53MGrant––
Sep 2017$1MGrant––
Jan 2017$15MSeries B–Amgen, Mission Bay Capital
Sep 2015$1.71MGrant––
Jul 2015$1.28MSeries A––
Sep 2014$1.5MSeries A–Sears Capital Management
Valuation history

16 investors in total: 16 institutional.

Investors in SiteOne Therapeutics

SiteOne Therapeutics has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Lilly and NIH.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Private equity and venture capital fund focused on the healthcare sector
novoholdings.dkHellerup, Denmark
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
1989orbimed.comNew York, United States
Investments in life science startups are made by Mission BioCapital.
missionbiocapital.comSan Francisco, United States
Limited information is provided about BSQUARED CAPITAL's activities.
bsq-c.com
Venture capital investments are provided to technology-driven startups.
nextfrontiercapital.comBozeman, United States
2m.com
A venture investment firm focused on life sciences is operated.
1994searscapital.net
biobrit.com
zipartners.com
US focused VC firm
missionbaycapital.comSan Francisco, United States
Premium access

Investor details for SiteOne Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of SiteOne Therapeutics

20 people are tracked at SiteOne Therapeutics (4 in leadership, 15 in board & advisors, 1 in team).

NameRoleGroup
John V. Mulcahy
Co-Founder & CEOLeadership
Joanne Bryce
Interim Chief Financial OfficerLeadership
John C. Hunter
Chief Scientific OfficerLeadership
Brian Wakabayashi
Vice President, Financial Planning And AnalysisLeadership
Michael C. Rowbotham
Scientific AdvisorBoard & advisors
Brendan Canning
Scientific AdvisorBoard & advisors
Rick Orr
DirectorBoard & advisors
Lowell E. Sears
DirectorBoard & advisors
Peter Dicpinigaitis
Scientific AdvisorBoard & advisors
Frank Porreca
Scientific AdvisorBoard & advisors
Stephen Wexler
Scientific AdvisorBoard & advisors
Stephen G. Waxman
Scientific AdvisorBoard & advisors
Stan E. Abel
DirectorBoard & advisors
Scott Braunstein
DirectorBoard & advisors
Will Price
DirectorBoard & advisors
Gary D. Novack
Scientific AdvisorBoard & advisors
Bradley J. Undem
Scientific AdvisorBoard & advisors
Justin Du Bois
DirectorBoard & advisors
Anthony Ford
Scientific AdvisorBoard & advisors
Anne Mcreynolds Martin
ControllerTeam
Premium access

Complete people profiles for SiteOne Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of SiteOne Therapeutics

4 dated milestones of SiteOne Therapeutics across 15 years, from founding to its latest funding, stage changes and deals.

  1. Founded SiteOne Therapeutics is founded.
  2. Funding First funding round of $3.1M.
  3. Funding Latest funding round, Series C, of $100.0M.
  4. Exit Acquired by Lilly.

Competitors of SiteOne Therapeutics

SiteOne Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Eliem Therapeutics and Zogenix.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
flexiontherapeutics.com2007Woburn, United States$62M692
Developer of therapies for the treatment of musculoskeletal disorders
eliemtx.com2018Boston, United States$171.3M30
Develops antibody-based treatments for autoimmune and inflammatory disorders.
zogenix.com2006Emeryville, United States$149.06M159
Drug delivery systems for CNS disorders and pain are developed.
Premium access

Detailed competitors of SiteOne Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of SiteOne Therapeutics

Websites that share an audience with SiteOne Therapeutics (siteonetherapeutics.com).

Similar websites

Websites whose visitors overlap most with SiteOne Therapeutics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
r2mpharma.com
100%
2.9K#4,331,217View details
circlepharma.com
98%
2.8K#6,088,315View details
corvuspharma.com
98%
13.6K#3,366,661View details
theranova.com
98%
View details
mandalmed.com
97%
1.3K#14,142,095View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 31 similar websites and full traffic analytics for SiteOne Therapeutics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 31 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Pain Management

3 companies that operate in the same segment as SiteOne Therapeutics (Pain Management) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of therapies for the treatment of musculoskeletal disorders
2007Woburn, Massachusetts, United StatesUSD 62 MUSD 85.55 M692
Developer of therapeutics for pain relief and inflammatory diseases
2004New York, New York, United StatesUSD 51 MUSD 4.33 M79
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed.
2007Philadelphia, Pennsylvania, United StatesUSD 203 MUSD 3.13 M35
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Siteone Therapeutics

Premium access

Complete news archive for SiteOne Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about SiteOne Therapeutics

SiteOne Therapeutics was founded in 2010 and raised its 1st funding round 2 years after it was founded.

SiteOne Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

John V. Mulcahy is the CEO of SiteOne Therapeutics, as recorded in our data. They have also founded this company.

SiteOne Therapeutics is a funded company, having raised a total of $123.78M across 13 funding rounds to date. The company's 1st funding round was a Series A of $1.5M, raised on Dec 2012.

SiteOne Therapeutics was founded in 2010 in San Francisco, United States, with operations centered in the biotechnology sector for pain management. Selective NaV1.7 inhibitors, derived from naturally occurring small molecules, are advanced as therapeutic candidates. The lead product, targeting moderate to severe pain, is currently in pre-clinical trials. Additional applications include long-acting analgesics and PET imaging diagnostics for various pain conditions.

SiteOne Therapeutics's top competitors include Flexion Therapeutics, Zogenix and Eliem Therapeutics.

SiteOne Therapeutics offers STC-004.

SiteOne Therapeutics has 16 investors. Key investors include Amgen, Lilly, NIH, HHS, and Orbimed.

SiteOne Therapeutics operates through Siteone Therapeutics, Inc..

Yes. SiteOne Therapeutics was acquired by Lilly in May 2025.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available